TABLE 3.

Summary of published studies assessing cytology‐histology concordance for PD‐L1 testing of non‐small cell lung carcinoma patients

Reference	Number of specimens	Antibody clone	Cytology‐histology concordance rate (kappa)
Ambrosini et al. 17	26	22C3	53.8% (k = 0.31)
Koomen et al. 18	47	22C3, SP263	57% (k = 0.49; 67% (k 0.590
Kuempers et al. 23	247	22C3	74.1%
Jug et al. 25	53	22C3	81.5% for adenocarcinoma, 76% for squamous cell carcinoma (k = 0.45)
Lou et al. 28	81	22C3	63% (k = 0.68)
Bortolloto et al. 29	20	22C3	90%
Wang et al. 35	34	22C3	91.2% (34 samples from different sites) and 100% (16 samples from same anatomic site)
Tsunoda et al. 37	30	22C3	86.7%
Lozano et al. 39	113	22C3	97.3%
Ilie et al. 41	70	22C3	97%
Xu et al. 42	52	22C3	k = 0.54 (adenocarcinoma), k = 0.34 (squamous cell carcinoma)
Wang et al. 43	29	22C3	Pearson correlation 0.925
Noll et al. 46	28 smears and nine cell block	22C3	High
Arriola et al. 47	30	22C3	80% (smears), 94.4% (cell blocks) and 62% (cell transfer from Pap stained smears)
Biswas et al. 48	50	22C3 28–8 SP263	k = 0.554 k = 0.698 k = 0.908
Capizzi et al. 49	21	22C3	93%
Chauhan et al. 51	40	SP263	82%
Gagne et al. 52	46	SP263	k = 0.56–0.82
Bozzetti et al. 53	52	SP263	92.3% (k = 0.731)
Ricci et al. 54	150	SP263	k = 0.534 (cut off of 1%) and k = 0.740 (>50% cut off)
Pak, Roh	58	SP263	94.34
Daverio et al. 56	138	SP263	k = 0.564
Hendry et al. 57	58	SP263	k = 0.39
Munari et al. 59	55	SP263	90.6 (50% cut off), 81.1% (1% cut off)
Jain et al. 60	26	SP263	88.4%
Dong et al. 61	112	28–8	k = 0.377–0.686
Skov 64	86	28–8 22C3	90% (50% cut off), 87% (1% cut off); 94% (50% cut off), 85% (1% cut off)

Abbreviation: PD‐L1, programmed death ligand 1.